tbuckley/cabot-search huggingface dataset:
OA02.06 The Sequential Therapy of Crizotinib Followed by Alectinib: Real World Data of 840 Patients with NSCLC Harboring ALK-Rearrangement (WJOG9516L)
Authors: S. Watanabe, T. Yamanaka, K. Ito, S. Sakata, H. Daga, T. Kijima, K. Hirano, I. Okamoto, A. Nakamura, T. Kozuki, M. Ishihara, K. Azuma, T. Seto, T. Yokoyama, Y. Oya, H. Kobayashi, K. Nishino, Y. Hattori, K. Nakagawa, N. Yamamoto
Journal: Journal of Thoracic Oncology (2019)
FDA considers Alzheimer’s drug previously abandoned for lack of effectiveness
Authors: Nigel Hawkes
Journal: BMJ (2019)

An Alzheimer’s drug that failed in two phase III trials and was abandoned as valueless has been brought back to life after an intensive examination of the trial results showed that it just might work in patients with early stage disease if the dose is right.

Aducanumab, developed by Biogen, joined a long list of failed Alzheimer’s treatments in March this year after the two trials found that it failed to slow the course of the disease. A similar drug from Eli Lilly also failed,1 leading analysts to conclude that the search for a treatment that was based on attacking amyloid plaques, the pathological signature of the disease, was doomed.

The failure hit Biogen hard, as it had created big expectations for aducanumab. So, drug company analysts showed …
Safety and efficacy of submucosal tunneling endoscopic septum division for epiphrenic diverticula
Authors: Xuan Li, Weifeng Zhang, Juliana Yang, Xiaoyong Wang, Yini Dang, Bin Hu, Qiang Cai, Pinghong Zhou, Guoxin Zhang
Journal: Endoscopy (2019)

Abstract Background Symptomatic epiphrenic diverticula are mostly treated with laparoscopic diverticulectomy. Our study aimed to demonstrate the safety and efficacy of submucosal tunneling endoscopic septum division (STESD) for treatment of symptomatic epiphrenic diverticula. Methods Data from patients with epiphrenic diverticula who had undergone STESD were retrospectively reviewed. The parameters analyzed were the modified Eckardt score, total procedure time, length of hospital stay (LOS), number of clips used, adverse events, and patient satisfaction. Results A total of eight patients (5 men; mean [standard deviation (SD)] age 66.25 [7.17] years) were enrolled in our study. The mean (SD) size of epiphrenic diverticula was 3.68 (1.59) cm. The mean (SD) procedure time was 52.87 (22.47) minutes, with a median number of six clips being applied. The modified Eckardt score significantly decreased post-procedure (P &lt; 0.001). The mean (SD) LOS was 5.87 (0.83) days. No adverse events or symptom recurrences were reported. Conclusion STESD is a safe and effective technique to be performed in the submucosal tunnel for the management of patients with epiphrenic diverticula.
P1.14-19 Exome Analysis of Patients Treated with Afatinib Reveals Genetic Variations Discriminating Extreme Responders
Authors: J. Niogret, C. Kaderbhai, S. Chevrier, C. Chapusot, C. Truntzer, H. Mananet, P. Foucher, B. Coudert, A. Lagrange, L. Favier, L. Martin, H. Almotlak, P. Jacoulet, J. Lahourcade, O. Adotevi, V. Westeel, L. Arnould, R. Boidot
Journal: Journal of Thoracic Oncology (2019)
Breast Implant–Associated Anaplastic Large Cell Lymphoma
Authors: Terence M. Myckatyn, Neha Mehta-Shah, Eric Duncavage
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
EP1.11-24 The TREAT Model 2.0: Predicting Lung Cancer in Patients Seeking Care in High-Risk Clinics
Authors: M. Shipe, A. Maiga, S. Deppen, V. Welty, J. Blume, M. Aldrich, C. Montgomery, A. Dickerson, J. Crockett, L. Vaszar, C. Williamson, S. Regis, B. Mckee, J. Isbell, O. Rickman, R. Pinkerman, E. Lambright, J. Nesbitt, P. Massion, E. Grogan
Journal: Journal of Thoracic Oncology (2019)
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Authors: Priyanka Sharma, William E. Barlow, Andrew K. Godwin, Eileen E. Parkes, Laura A. Knight, Steven M. Walker, Richard D. Kennedy, Denis P. Harkin, Gemma E. Logan, Christopher J. Steele, Shauna M. Lambe, Sunil Badve, Yesim Gökmen-Polar, Harsh B. Pathak, Kamilla Isakova, Hannah M. Linden, Peggy Porter, Lajos Pusztai, Alastair M. Thompson, Debu Tripathy, Gabriel N. Hortobagyi, Daniel F. Hayes
Journal: Journal of Clinical Oncology (2019)

To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313.Four hundred twenty-five centrally determined patient cases with TNBC from S9313 were identified. DDIR signature was performed on RNA isolated from formalin-fixed paraffin-embedded tumor tissue, and samples were classified as DDIR negative or positive using predefined cutoffs. Evaluation of sTILs was performed as described previously. Markers were tested for prognostic value for disease-free survival (DFS) and overall survival (OS) using Cox regression models adjusted for treatment assignment, nodal status, and tumor size.Among 425 patients with TNBC, 33% were node positive. DDIR was tested successfully in 90% of patients (381 of 425), 62% of which were DDIR signature positive. DDIR signature positivity was associated with improved DFS (hazard ratio [HR], 0.67; 95% CI, 0.48 to 0.92; P = .015) and OS (HR, 0.61; 95% CI, 0.43 to 0.89; P = .010). sTILs density assessment was available in 99% of patients and was associated with improved DFS (HR, 0.70; 95% CI, 0.51 to 0.96; P = .026 for sTILs density ≥ 20% v < 20%) and OS (HR, 0.59; 95% CI, 0.41 to 0.85; P = .004 for sTILs density ≥ 20% v < 20%). DDIR signature score and sTILs density were moderately correlated (r = 0.60), which precluded statistical significance for DFS in a joint model. Three-year DFS and OS in a subgroup of patients with DDIR positivity and T1c/T2N0 disease were 88% and 94%, respectively.The prognostic role of sTILs and DDIR in early-stage TNBC was confirmed. DDIR signature conferred improved prognosis in two thirds of patients with TNBC treated with adjuvant AC. DDIR signature has the potential to stratify outcome and to identify patients with less projected benefit after AC chemotherapy.
P1.01-133 Randomized Open-Label Study of Bintrafusp Alfa (M7824) vs Pembrolizumab in Patients with PD-L1 Expressing Advanced 1L NSCLC
Authors: M. Ahn, F. Barlesi, E. Felip, E. Garon, C. Martin, T. Mok, E. Vokes, L. Ojalvo, A. Koenig, I. Dussault, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2019)
P2.16-24 Prognostic Value of RDW, NLR and CYFRA 21-1 in Overall Survival of Patients with Metastatic NSCLC
Authors: C.J. Flores, A. Aguilar, L. Mas, D. Enriquez, J.M. Gutierrez, L. Schwarz, C. Vallejos
Journal: Journal of Thoracic Oncology (2019)
P2.03-11 Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas
Authors: S. Martins-Filho, A. Fares, V. Raghavan, E. Stewart, D. Ravi, K. Perdrizet, J. Weiss, K. Hueniken, D. Patel, N. Pham, A. Sacher, P. Bradbury, N. Leighl, F. Shepherd, M. Tsao, G. Liu
Journal: Journal of Thoracic Oncology (2019)
P1.04-38 Efficacy and Safety of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer
Authors: G. Galli, A. De Toma, F. Pagani, G. Randon, B. Trevisan, A. Prelaj, R. Ferrara, C. Proto, D. Signorelli, M. Ganzinelli, N. Zilembo, F. De Braud, M. Garassino, G. Lo Russo
Journal: Journal of Thoracic Oncology (2019)
P1.14-35 Epithelial-To-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Authors: K. Fukuda, S. Takeuchi, S. Arai, S. Nanjo, R. Katayama, K. Takeuchi, M. Nishio, S. Yano
Journal: Journal of Thoracic Oncology (2019)
The Tmprss6-/- Mouse Model of Iron Refractory Iron Deficiency Anemia (IRIDA) Exhibits Disrupted Phosphate Homeostasis, Elevated Circulating FGF23 Levels, and Increased Fgf23 Expression in Bone Marrow
Authors: Xiuqi Li, Larisa Lozovatsky, Abitha Sukumaran, Steven Tommasini, Jackie A. Fretz, Karin E. Finberg
Journal: Blood (2017)
P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
Authors: A. Sezer, M. Gogishvili, D. Bentsion, S. Kilickap, A. Lowczak, M. Gumus, O. Gladkov, P. Clingan, V. Sriuranpong, N. Rizvi, S. Lee, S. Li, P. Snodgrass, M. Navarro, I. Lowy, P. Rietschel
Journal: Journal of Thoracic Oncology (2019)
P2.17-13 Thoracoscore Fails to Predict In-Hospital Mortality Following Elective Surgery in a Brazilian Lung Cancer Cohort
Authors: E. Ricardo, F. Abrao, F. Moreira, I. Abreu, R. Younes, O. Da Rocha Neto, V.J. Agostinho
Journal: Journal of Thoracic Oncology (2019)
OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses
Authors: J. Wolf, Å. Helland, I. Oh, M.R. Migliorino, R. Dziadziuszko, J. De Castro Carpeno, J. Mazieres, F. Griesinger, M. Chlistalla, A. Cardona, T. Ruf, K. Trunzer, V. Smoljanovic, S. Novello
Journal: Journal of Thoracic Oncology (2019)
P1.04-79 CD73 Expression in Lung Adenocarcinomas and Immunological and Molecular Associations
Authors: P. Rocha, R. Salazar, J. Solorzano, J. Zhang, B. Mino, E. Parra, D. Ledesma, H. Kadara, J. Zhang, A. Vaporciyan, D. Rice, N. Kalhor, C. Moran, D. Gibbons, A. Weissferdt, B. Sepesi, I. Wistuba, C. Behrens, L. Solis
Journal: Journal of Thoracic Oncology (2019)
EP1.15-22 Primary Epithelial - Myoepithelial Carcinoma of the Lung with Unexpected Aggressive Onset
Authors: S. Ricciardi, G. Alì, E. Marrama, A. Nesti, P. Dini, V. Aprile, G. Fontanini, M. Lucchi
Journal: Journal of Thoracic Oncology (2019)
P2.04-60 Pembrolizumab-Based Regimens Administered at Non-Standard Frequency in Non-Small Cell Lung Cancer (NSCLC)
Authors: K. Sehgal, M. Shea, D. Mcdonald, M. Huberman, G. Weiss, P. Vanderlaan, D. Costa, D. Rangachari
Journal: Journal of Thoracic Oncology (2019)
P1.01-49 Serial Changes in Whole-Genome Cell-Free DNA (cfDNA) to Identify Disease Progression Prior to Imaging in Advanced NSCLC
Authors: A. Davis, W. Iams, D. Chan, M. Oh, R. Lentz, N. Peterman, A. Robertson, A. Shah, R. Srivas, N. Lambert, T. Wilson, A. Tezcan, J. Spinosa, H. Tezcan, N. Mohindra, V. Villaflor, Y.K. Chae
Journal: Journal of Thoracic Oncology (2019)
MA21.01 Generation and Characterization of Novel Preclinical Disease Models of NSCLC with NRG1 Rearrangements to Improve Therapy
Authors: E. Gladstone, M. Vojnic, M. Offin, L. Delasos, A. Lui, E. Siau, H. Sato, R. Benayed, R. Kurth, M. Mattar, I. Khodos, E. De Stanchina, R. Daly, A. Schram, A. Drilon, M. Ladanyi, R. Somwar
Journal: Journal of Thoracic Oncology (2019)
MA25.08 Characterisation of Tumor Aetiology Using Mutational Signatures from the Non-Small Cell Lung Cancer Genome
Authors: C. Lindsay, S. Rafee, P. Nicola, A. Wallace, G. Burghel, H. Schlecht, K. Baker, E. Baker, L. Priest, J. Rogan, S. Moghadam, M. Carter, W. Newman, F. Blackhall
Journal: Journal of Thoracic Oncology (2019)
EP1.03-03 Association Between Molecular Spectrum of EZH2 Variants and Prognosis in Patients with Non-Small-Cell Lung Cancer in Chinese Patients
Authors: H. Wang, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
The Single-Clinician–Operator/Anesthetist Model for Dental Deep Sedation/Anesthesia
Authors: Charles J. Coté, Raeford E. Brown, Anna Kaplan
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion
Authors: Ilaria Del Giudice, Silvia Bonina, Marilisa Marinelli, Luciana Cafforio, Sara Raponi, Eloise Boldrini, Alexia Bonafede, Simona Tavolaro, Caterina Ilari, Monica Messina, Sabina Chiaretti, Francesca Romana Mauro, Alfonso Piciocchi, Sonia Maria Orlando, Gian Matteo Rigolin, Antonio Cuneo, Davide Rossi, Gianluca Gaidano, Anna Guarini, Robin Foá
Journal: Blood (2014)
P1.14-25 Targeting NRG1-Fusions in Lung Adenocarcinoma: Afatinib as a Novel Potential Treatment Strategy
Authors: M. Duruisseaux, J.J. Laskin, K. Tolba, E. Brandén, Y. Goto, R. Doebele, P.K. Cheema, J. Cadranel, M.R. Jones, A. Drilon, D. Trombetta, L.A. Muscarella, A. Cseh, F. Solca, S. Liu
Journal: Journal of Thoracic Oncology (2019)
OA10.02 Recommended Change for N Descriptor Proposed by the IASLC: A Validation Study from a Single-Center Experience
Authors: B.J. Park, T.H. Kim, S. Shin, H.K. Kim, Y.S. Choi, J. Kim, J.I. Zo, Y.M. Shim, J.H. Cho
Journal: Journal of Thoracic Oncology (2019)
P2.16-37 Impact of Brain Metastases on Healthcare Utilisation and Costs in Patients with NSCLC Treated with EGFR-TKIs
Authors: D. Subramaniam, M. Pavilack, H. Huo, R. Shenolikar, A. Kong, M. Moynihan, E. Marchlewicz, C. Larson
Journal: Journal of Thoracic Oncology (2019)
Complete Spontaneous Regression of Hepatosplenic T-Cell Lymphoma After Surgical Biopsy
Authors: Ryusuke Nakamoto, Chio Okuyama, Satoshi Oka
Journal: Clinical Nuclear Medicine (2019)

Abstract 18 F-FDG PET/CT for a 74-year-old man with elevated serum soluble interleukin 2 receptor showed multiple intense uptake in the liver, spleen, and bone. A surgical biopsy from 2 of liver tumors confirmed hepatosplenic αβ T-cell lymphoma. One and a half months after biopsy, FDG PET scan was performed again for staging before starting chemotherapy, and it showed the complete disappearance of all of the lesions. The excisional biopsy could be a possible trigger of his spontaneous regression.
Posterior-Wall Myocardial Infarction
Authors: Andre Briosa E Gala, John Rawlins
Journal: New England Journal of Medicine (2019)

A 60-year-old woman presented to the emergency department with acute chest pain. Initial electrocardiography was suggestive of posterior-wall ischemia. An ECG performed with the use of posterior leads revealed ST-segment elevation in leads V7, V8, and V9, which was consistent with posterior-wall myocardial infarction.
A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias
Authors: Z. Estrov, J. Cortes, G. Borthakur, S. Faderl, G. Garcia Manero, F. Ravandi, J. Khoury, M. Ptaszynski, H. Kantarjian
Journal: Journal of Clinical Oncology (2009)

7022 ARRY-520 is a potent, selective KSP inhibitor that arrests cells in mitosis with the subsequent onset of apoptosis. ARRY-520 has shown potent activity in preclinical models of hematological cancers and is being evaluated in a phase I trial in patients with advanced or refractory leukemias. The primary objectives of this study are to establish the safety and the MTD of ARRY-520 given as a single dose each cycle. Secondary objectives are to characterize the pharmacokinetics (PK) of ARRY-520, to assess evidence of preliminary clinical activity, and to explore biomarkers of KSP inhibition. ARRY-520 is administered as a 1-h IV infusion as a single dose per cycle in a “3 + 3 phase I design”. Dose escalations are following a prespecified schema. PK analyses for ARRY-520 are performed on plasma samples collected during cycle 1 and cycle 2. Pretreatment and post-treatment peripheral blood samples are collected for analysis of markers of KSP activity. To date, 15 patients, with a median age of 69 yrs (range 44–84 yrs), have been enrolled in the single dose schedule, 3 patients each at doses of 2.5 mg/m2, 3.75 mg/m2, and 5.6 mg/m2 and 6 patients at 4.5 mg/m2 per cycle. All patients had disease refractory to, and/or relapsed from, 1 or more prior therapies with a median of 3 prior regimens (range 1–10). Two patients at 5.6 mg/m2 experienced a DLT of gr3 mucositis. ARRY-520 was well tolerated at doses below 5.6 mg/m2. 4.5 mg/m2 has been determined to be the MTD. ARRY-520 has shown promising signs of clinical activity at doses of 3.75 mg/m2 and above. 2 patients had a complete reduction in their peripheral blasts on day 5 of cycle 1. Of these, one patient experienced a 70% reduction in bone marrow blasts while on study. One patient without peripheral blood blasts at baseline had a 43% reduction in bone marrow blasts and four additional patients had marked reductions in WBC counts. This is the first reported use of a KSP inhibitor in refractory and/or relapsed leukemias. ARRY-520 has been well tolerated in patients on a single dose schedule. Mucositis was observed as the DLT at 5.6 mg/m2. At doses 3.75 mg/m2 and above, ARRY-520 has shown signs of clinical activity. Based on these data, an alternative dose schedule is being explored. Updated data including safety, PK, PD, and preliminary activity of ARRY 520 from this study will be presented. [Table: see text]
P2.06-22 Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?
Authors: T. Basoglu Tuylu, N.C. Demircan, R. Arikan, T. Akin Telli, O. Alan, O. Ercelep, E. Bozkurtlar, D. Kocakaya, S. Kaya, N. Babacan, T. Lacin, F. Dane, R. Ahiskali, H. Batirel, P.F. Yumuk
Journal: Journal of Thoracic Oncology (2019)
Improving the System to Support Clinician Well-being and Provide Better Patient Care
Authors: Pascale Carayon, Christine Cassel, Victor J. Dzau
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy
Authors: S. Baglivo, F. Bianconi, F. Tofanetti, B. Ricciuti, L. Pistola, A. Siggillino, M. Reda, G. Metro, G. Bellezza, V. Minotti, F. Roila, V. Ludovini
Journal: Journal of Thoracic Oncology (2019)
Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial
Authors: Martin Bornhaeuser, Uta Oelschlaegel, Gesine Bug, Uwe Platzbecker, Karin Lutterbeck, Michael G Kiehl, Johannes Schetelig, Alexander Kiani, Thomas Illmer, Markus Schaich, Catrin Theuser, Brigitte Mohr, Cornelia Brendel, Axel A Fauser, Stefan Klein, Hans Martin, Gerhard Ehninger, Christian Thiede
Journal: Blood (2008)
OA07.01 Osimertinib Plus Platinum/Pemetrexed in Newly-Diagnosed Advanced EGFRm-Positive NSCLC; The Phase 3 FLAURA2 Study
Authors: P. Jänne, D. Planchard, P. Howarth, A. Todd, K. Kobayashi
Journal: Journal of Thoracic Oncology (2019)
P1.04-04 DNA Damage Response Gene Alterations Are Associated with High Tumor Mutational Burden and Clinical Benefit from PD-1 Axis Inhibition in NSCLC
Authors: B. Ricciuti, M. Cheng, G. Recondo, R. Umeton, M. Nishino, L. Sholl, M. Awad
Journal: Journal of Thoracic Oncology (2019)
P1.01-36 Clinical Potential of Tissue Tumor Mutational Burden (tTMB) and Blood TMB (bTMB) as a Biomarker in Non-Small Cell Lung Cancer
Authors: J. Zhou, J. Zhou, X. Chen, Y. Zhu, L. Fang, Z. Bao, R. Liu, H. Cao, W. Sun, T. Zhang, J. Lin, B. Yu
Journal: Journal of Thoracic Oncology (2019)
P2.09-09 EGFR Is Highly Mutated in Lung Adenocarcinoma Patients with History of Breast Cancer
Authors: A. Sakurada, K. Sato, H. Notsuda, H. Oishi, Y. Matsuda, T. Sado, M. Noda, Y. Okada
Journal: Journal of Thoracic Oncology (2019)
Tumor Mutation Burden—From Doubts to Concerns—In Reply
Authors: Alfredo Addeo, Giuseppe L. Banna, Glen J. Weiss
Journal: JAMA Oncology (2019)

In Reply We have read the comment from Wood et al about our Viewpoint,1 and we share their concern about the hurdles that tumor mutation burden (TMB) presents for standard-of-care use in the clinical setting.
Stem-cell-derived human microglia transplanted in mouse brain to study human disease
Authors: Renzo Mancuso, Johanna Van Den Daele, Nicola Fattorelli, Leen Wolfs, Sriram Balusu, Oliver Burton, Adrian Liston, Annerieke Sierksma, Yannick Fourne, Suresh Poovathingal, Amaia Arranz-Mendiguren, Carlo Sala Frigerio, Christel Claes, Lutgarde Serneels, Tom Theys, V. Hugh Perry, Catherine Verfaillie, Mark Fiers, Bart De Strooper
Journal: Nature Neuroscience (2019)